Neuphoria Therapeutics (NEUP) Consolidated Net Income (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Consolidated Net Income of -$505063.0 for Q1 2026, down 104.48% year-over-year from $11.3 million in Q1 2025, and down 127.09% quarter-over-quarter from $1.9 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Consolidated Net Income (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Consolidated Net Income for 4 consecutive years, with -$505063.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Consolidated Net Income fell 104.48% year-over-year to -$505063.0; the TTM figure through Mar 2026 stood at -$10.8 million (down 274.0% YoY), while the FY2025 annual figure was $6.3 million, up 141.49% from the prior year.
- Consolidated Net Income declined to -$505063.0 in Q1 2026 per NEUP's latest filing, from $1.9 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at $11.3 million in Q1 2025 and bottomed at -$9.9 million in Q3 2025.
- Historically, Consolidated Net Income has averaged -$1.6 million across 4 years, with a median of -$2.2 million in 2025.
- On a YoY basis, Consolidated Net Income climbed as much as 505.38% in 2025 and fell as far as 1130.95% in 2025.
- Neuphoria Therapeutics' Consolidated Net Income stood at -$4.6 million in 2023, then soared by 57.33% to -$1.9 million in 2024, then jumped by 195.92% to $1.9 million in 2025, then tumbled by 127.09% to -$505063.0 in 2026.
- Business Quant data shows NEUP's Consolidated Net Income at -$505063.0 in Q1 2026, $1.9 million in Q4 2025, and -$9.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - | -505,063.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -505,063.00 |
| Dec 31, 2025 | 1.86 Mn |
| Sep 30, 2025 | -9.91 Mn |
| Jun 30, 2025 | -2.24 Mn |
| Mar 31, 2025 | 11.26 Mn |
| Dec 31, 2024 | -1.94 Mn |
| Sep 30, 2024 | -804,787.00 |
| Jun 30, 2024 | -2.31 Mn |
| Mar 31, 2024 | -2.78 Mn |
| Dec 31, 2023 | -4.55 Mn |
| Sep 30, 2023 | -5.47 Mn |